{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:55:14Z","timestamp":1783403714965,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40644-017-0133-5","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T08:11:36Z","timestamp":1513843896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5835","authenticated-orcid":false,"given":"Amir","family":"Iravani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal K.","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467\u201379.","journal-title":"Eur Urol"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/v10019-010-0050-8","volume":"45","author":"M Hodolic","year":"2011","unstructured":"Hodolic M. Role of (18)F-choline PET\/CT in evaluation of patients with prostate carcinoma. Radiol Oncol. 2011;45:17\u201321.","journal-title":"Radiol Oncol"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2478\/v10019-009-0038-4","volume":"43","author":"A Horvat","year":"2009","unstructured":"Horvat A, Kova\u010d V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases. Radiol Oncol. 2009;43:213\u201324.","journal-title":"Radiol Oncol"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61\u201371.","journal-title":"Eur Urol"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"921674","DOI":"10.1155\/2012\/921674","volume":"2012","author":"S Kosuri","year":"2012","unstructured":"Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol. 2012;2012:921674.","journal-title":"Adv Urol"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM Hovels","year":"2008","unstructured":"Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387\u201395.","journal-title":"Clin Radiol"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0090-4295(96)00161-6","volume":"48","author":"RC Flanigan","year":"1996","unstructured":"Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, Waters WB. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology. 1996;48:428\u201332.","journal-title":"Urology"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","volume":"40","author":"M Eder","year":"2013","unstructured":"Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"133_CR13","unstructured":"Eiber M, Maurer T, Beer AJ, Souvatzoglou M, Weirich G, Kubler H: Prospective evaluation of PSMA-PET imaging for preoperative lymph node staging in prostate cancer J Nucl Med 2014 55 (Supplement 1)."},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"W263","DOI":"10.2214\/AJR.09.4181","volume":"195","author":"OJ O'Connor","year":"2010","unstructured":"O'Connor OJ, Fitzgerald E, Maher MM. Imaging of hematuria. AJR Am J Roentgenol. 2010;195:W263\u20137.","journal-title":"AJR Am J Roentgenol"},{"key":"133_CR16","doi-asserted-by":"crossref","first-page":"69141S","DOI":"10.1117\/12.770352","volume":"6914","author":"JM Reinhardt","year":"2008","unstructured":"Reinhardt JM, Maleike D, Pluim JPW, Fabel M, Tetzlaff R, von Tengg-Kobligk H, Heimann T, Meinzer H-P, Wolf I. Lymph node segmentation on CT images by a shape model guided deformable surface methodh. Proc SPIE. 2008;6914:69141S.","journal-title":"Proc SPIE"},{"key":"133_CR17","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/j.ijrobp.2014.05.1407","volume":"90","author":"F Sterzing","year":"2014","unstructured":"Sterzing F, Fiedler H, Stefanova M, Afshar-Oromieh A, Kratochwil C, Debus J, Haberkorn U, Giesel F. Impact of 68Ga-PSMA PET\/CT in Staging of Prostate Cancer Patient Prior to Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 2014;90:S449.","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GL Wright Jr","year":"1996","unstructured":"Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326\u201334.","journal-title":"Urology"},{"key":"133_CR19","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"133_CR20","first-page":"1803","volume":"47","author":"EM Kamel","year":"2006","unstructured":"Kamel EM, Jichlinski P, Prior JO, Meuwly JY, Delaloye JF, Vaucher L, Malterre J, Castaldo S, Leisinger HJ, Delaloye AB. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med. 2006;47:1803\u20137.","journal-title":"J Nucl Med"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40644-016-0072-6","volume":"16","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET\/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.","journal-title":"Cancer Imaging"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582\u20137.","journal-title":"Nucl Med Commun"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/rg.2015140209","volume":"35","author":"SE Potenta","year":"2015","unstructured":"Potenta SE, D'Agostino R, Sternberg KM, Tatsumi K, Perusse K, Urography CT. For evaluation of the ureter. Radiographics. 2015;35:709\u201326.","journal-title":"Radiographics"},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00330-008-1174-8","volume":"19","author":"S Cirillo","year":"2009","unstructured":"Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D. Endorectal magnetic resonance imaging at 1.5 tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. 2009;19:761\u20139.","journal-title":"Eur Radiol"},{"key":"133_CR25","doi-asserted-by":"crossref","unstructured":"Panebianco V, Barchetti F, Grompone MD, Colarieti A, Salvo V, Cardone G, Catalano C. Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence. Urol Oncol. 2016;34:303-310.","DOI":"10.1016\/j.urolonc.2016.01.004"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, Bonekamp D, Kopka K, Eder M, Heusser T, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"133_CR28","first-page":"608","volume":"46","author":"G Brix","year":"2005","unstructured":"Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, Beyer T. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET\/CT examinations. J Nucl Med. 2005;46:608\u201313.","journal-title":"J Nucl Med"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2967\/jnumed.109.065912","volume":"50","author":"AM Alessio","year":"2009","unstructured":"Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT. Weight-based, low-dose pediatric whole-body PET\/CT protocols. J Nucl Med. 2009;50:1570\u20137.","journal-title":"J Nucl Med"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.semnuclmed.2007.05.002","volume":"37","author":"MJ Gelfand","year":"2007","unstructured":"Gelfand MJ, Lemen LC. PET\/CT and SPECT\/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med. 2007;37:391\u20138.","journal-title":"Semin Nucl Med"},{"key":"133_CR31","doi-asserted-by":"crossref","unstructured":"Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U, Kratochwil C. PSMA PET\/CT with Glu-urea-Lys-(Ahx)-[(6)(8)Ga(HBED-CC)] versus 3D CTvolumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1794-1800.","DOI":"10.1007\/s00259-015-3106-6"},{"key":"133_CR32","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320.","DOI":"10.1007\/s00259-013-2525-5"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-017-0133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T08:11:51Z","timestamp":1513843911000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-017-0133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1186\/s40644-017-0133-5","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"31"}}